Explore the words cloud of the FAITh project. It provides you a very rough idea of what is the project "FAITh" about.
The following table provides information about the project.
Coordinator |
WEIZMANN INSTITUTE OF SCIENCE
Organization address contact info |
Coordinator Country | Israel [IL] |
Total cost | 150˙000 € |
EC max contribution | 150˙000 € (100%) |
Programme |
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC)) |
Code Call | ERC-2017-PoC |
Funding Scheme | ERC-POC |
Starting year | 2017 |
Duration (year-month-day) | from 2017-11-01 to 2019-04-30 |
Take a look of project's partnership.
# | ||||
---|---|---|---|---|
1 | WEIZMANN INSTITUTE OF SCIENCE | IL (REHOVOT) | coordinator | 150˙000.00 |
Anxiety and stress-related conditions represent a significant health burden in modern society. Anxiety disorders are currently treated with a variety of agents targeting synaptic mechanisms. These agents either directly affect neurotransmitter receptor systems or modulate neurotransmitter levels or availability, but their long-term use is limited by problematic side effects and suboptimal efficacy. The development of new anxiolytic drugs has been fraught with difficulty, hence there is a need for new targets and new avenues for therapeutic development.
Importin-dependent transport mechanisms link synapse to nucleus in a diversity of physiological contexts, rendering them potentially interesting targets for behavioural control. However importins and related molecules have not been evaluated for roles in anxiolysis to date. We discovered the roles of importins in axonal injury signaling and in cell size sensing. During the course of our current ERC Advanced grant, and as part of one of the aims, we have conducted comprehensive phenotyping of importin mouse mutants to identify in vivo consequences of the deregulation of size control pathways. One importin mutant line presented a specific phenotype in anxiety tests, and follow-up analyses identified a new molecular pathway for anxiety regulation, and approved drugs affecting this pathway that can be repositioned for anxiety treatment.
In this PoC, we will (1) carry out IP protection on our initial identifications of anxiolytic drugs; (2) further validate the anxiolytic activities of these drugs and their closely related structural or functional analogs; and (3) devise an HTS-compatible assay for targeting the importin involved and conduct a pilot screen of ~200,000 compounds in this assay to identify new drug leads for anxiety treatment. As a final step, we will carry out (4) additional IP protection and pre-commercialisation tasks for maximizing the commercialisation potential of our discovery.
year | authors and title | journal | last update |
---|---|---|---|
2018 |
Nicolas Panayotis, Anton Sheinin, Shachar Y. Dagan, Michael M. Tsoory, Franziska Rother, Mayur Vadhvani, Anna Meshcheriakova, Sandip Koley, Letizia Marvaldi, Didi-Andreas Song, Eitan Reuveny, Britta J. Eickholt, Enno Hartmann, Michael Bader, Izhak Michaelevski, Mike Fainzilber Importin α5 Regulates Anxiety through MeCP2 and Sphingosine Kinase 1 published pages: 3169-3179.e7, ISSN: 2211-1247, DOI: 10.1016/j.celrep.2018.11.066 |
Cell Reports 25/11 | 2019-09-04 |
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FAITH" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FAITH" are provided by the European Opendata Portal: CORDIS opendata.